1250P Camrelizumab plus apatinib combined with POF in patients with untreated advanced gastric cancer (UAGC): A single-center, open-label, single-arm, phase II trial (SYLT-017)
L. Su, S. Zhao, P. Lin, Y. Yin, R. Lin
Topics & Concepts
MedicineApatinibOpen labelSingle CenterCancerOncologyInternal medicineClinical trialGastric Cancer Management and OutcomesGastrointestinal Tumor Research and TreatmentMetastasis and carcinoma case studies